a total of 50 evaluable adult patients with relapsing lymphoma and two with hodgkin 's disease received bisantrene by central iv catheter every 3 weeks , at doses of 350 mg/m2 for patients with adequate marrow reserve and 300 mg/m2 for those with compromised marrow reserve .
C0024299
lymphoma
C0019829
hodgkin 's disease